BREAKING: Futures Jump On Megacap Tech Earnings Alexion Pharmaceuticals (ALXN) topped first-quarter estimates Wednesday, but the biotech company trimmed its full-year outlook amid the coronavirus pandemic.Both metrics beat the average estimate of analysts polled by Zacks Investment Research for Alexion earnings of $2.70 a share and $1.35 billion in sales.